N ANTHONY COLES
CIK 1197018 · CEO and Chairperson · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.74M
Companies
10
Total Filings
89
Lifetime Open-Market Net
-$78.50M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| REGN | Director | 1,714 | $612.14 | $1.05M | -$20.62M | 16 | 2026-01-06 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 25,928 | $44.96 | $1.17M | -$30.40M | 22 | 2024-07-03 |
| KINETA, INC./DE (YMTX) Delisted | Executive Chair | 743,677 | $13.23 | $9.84M | $0 | 3 | 2021-04-02 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | President and CEO | — | $18.07 | — | $0 | 2 | 2021-02-05 |
| MCK | Director | 0 | $784.05 | $0 | -$558.3K | 9 | 2020-08-19 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | 70,000 | — | — | $0 | 3 | 2017-06-02 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Chairman & CEO | 131,198 | — | — | -$26.92M | 17 | 2013-06-07 |
| Campus Crest Communities, Inc. (RLD) Delisted | Director | 3,999 | — | — | $0 | 4 | 2013-05-31 |
| LH | Director | 2,584 | $266.16 | $687.8K | $0 | 4 | 2013-02-19 |
| NPS PHARMACEUTICALS INC (NPSP) Delisted | President, COO & Director | 147,638 | — | — | $0 | 7 | 2008-03-18 |
Recent Filings · Page 5 of 9
89 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-08-19 | MCK | Sell (S) | −2,453 | -$384.6K | EDGAR |
| 2020-07-31 | MCK | Grant (A) | +1,157 | $0 | EDGAR |
| 2020-01-06 | REGN | Grant (A) | +320 | $0 | EDGAR |
| 2019-08-01 | MCK | Grant (A) | +1,296 | $0 | EDGAR |
| 2019-01-04 | REGN | Grant (A) | +323 | $0 | EDGAR |
| 2018-09-04 | MCK | Sell (S) | −1,350 | -$173.7K | EDGAR |
| 2018-07-26 | MCK | Grant (A) | +1,350 | $0 | EDGAR |
| 2018-01-04 | REGN | Grant (A) | — | $0 | EDGAR |
| 2017-07-27 | MCK | Grant (A) | — | $0 | EDGAR |
| 2017-06-02 | CRISPR Therapeutics AG (PZRX) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.